Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nymox Pharmaceutical Corp (NASDAQ:NYMX)

2.21
Delayed Data
As of Aug 28
 +0.03 / +1.38%
Today’s Change
0.33
Today|||52-Week Range
5.55
+452.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$82.2M

Company Description

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which specializes in the research and development of products for the aging population. Currently, it markets NicAlertTM and TobacAlertTM, tests that use urine or saliva to detect use of tobacco products. The company develops NX-1207, a novel treatment for benign prostatic hyperplasia, which is in Phase 3 clinical trials. It also has pipeline drug candidates aimed at the causes of Alzheimer's disease and new treatments of bacterial infections in humans. Nymox Pharmaceutical was founded by Paul Averback on May 30, 1995 and is headquartered in St.-Laurent, Canada.

Contact Information

Nymox Pharmaceutical Corp.
9900, boulevard Cavendish
Saint-Laurent Quebec H4M 2V2
P:(800) 936-9669
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Paul AverbackChairman, President & Chief Executive Officer
Erik DanielsenChief Financial Officer